# Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment

> **NCT02259855** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 36 (actual)

## Conditions studied

- Hepatic Insufficiency

## Interventions

- **DRUG:** Tipranavir
- **DRUG:** Ritonavir
- **DRUG:** Pegylated interferon
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT02259855
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01-01
- **Primary completion:** 2008-10-01
- **Final completion:** —
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02259855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02259855, "Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02259855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*